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ABSTRACT 
Background 
Cervical cancer is the 3
rd
 most common female malignancy worldwide. It is classified and 
managed according to stage as defined by the FIGO Committee on Gynaecology Oncology 
classification of 2009. Stage specific treatment is tailored according to prognosis and risk of 
recurrence as determined by tumour type, tumour size, tumour grade, lymph node metastases, 
lymphovascular space involvement (LVSI), parametrial spread and presence of any other 
metastatic deposits at presentation. This study only concentrated on patients who presented with 
Stage IB1 and 1B2 tumours managed by Class III / Meig’s Radical / Wertheim’s hysterectomy and 
bilateral pelvic lymphadenectomy.  
 
Aims 
Primary Outcome 
1. Assess disease free interval and overall survival 2 years post-operatively. 
Secondary Outcomes 
1. Assess adequacy of patient selection  
2. Assess risk factors for recurrence 
3. Compare recurrence risk of HIV positive patients versus HIV negative patients. 
4. Determine surgical and post-surgical complication rate. 
 
Materials and Methods 
This was a retrospective institutional cohort study conducted at the Charlotte Maxeke 
Johannesburg Academic Hospital. All patients with Stage IB1 or IB2 cervical cancer treated with 
Wertheim hysterectomies between 2002 and 2012 were included.  
viii 
 
Surgical records, histology records, further postoperative management records and gynaecological 
outpatient follow up records were used to collect data for the patients.  
Histological findings post-operatively determined further management. Surgical margins had to be 
10mm clear of tumour with no positive lymph nodes otherwise external beam radiotherapy and 
brachytherapy or chemo-radiotherapy were recommended in addition to primary surgical 
management.  
 
Results 
Of the 72 patients initially identified, 69 patients were suitable for study inclusion. The mean age 
of the study population was 45 years.  Study population racial distribution: 68.12% were Black, 
26.09% were White, 2.9% were Coloured and 2.9% were Indian. Average parity and gravidity of 
patients alive at the end of the study was 2.86 and 3.56; while average parity and gravidity of 
patients deceased at the end of the study was 2.5 and 2.8 respectively. Study population ECOG 
status: 16% were ECOG 0, 83% were ECOG 1 and 1% were ECOG 2. Overall survival at the end 
of the study was 86% and patients were disease free postoperatively for an average of 5 years. 
Thirty three percent of the patients were disease free for more than 5 years. Preoperative clinical 
staging and postoperative histological staging correlated only in 61% of cases. Correct 
management by Wertheim’s hysterectomy was rendered to 75% of patients whereas the remainder 
were incorrectly managed and should have had either a simple hysterectomy with no pelvic 
lymphadenectomy or radiotherapy only as primary therapy. More advanced stages, tumours ≥ 
4cm, adenomatous cell type, > 5mm depth of invasion, >7mm lateral spread, higher number of 
nodes positive for metastatic disease, surgical margins  10mm, positive lympohovascular space, 
parametrial and pouch of Douglas (POD) involvement were factors that had a poorer prognosis 
with regards overall survival, disease-free interval or both. Poorly differentiated tumours were 
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more likely to recur but did not have a poorer prognosis compared with regards to overall survival 
or disease free interval at 2 or more years compared to well and moderately differentiated tumours. 
Mortality of HIV reactive patients was 16.7% compared to 12.5% for HIV non-reactive patients. 
This difference was not statistically significant at the 95% confidence level.  HIV status also did 
not increase risk of recurrence. Lower CD4 counts were shown to have a lower disease-free period 
and overall survival. Intra-operative surgical complication rate was 6%. Immediate post-operative 
complication rate was 16%. Of the patients who required DXT or DXT and chemotherapy 33% 
had side-effects or complications from adjuvant therapy. Patients treated with DXT and 
chemotherapy had had more side-effects than those treated with DXT only. 
 
Conclusion 
The mean age of the study population was 45 years. This was lower compared to other larger 
studies possibly due to younger presentation related to HIV disease. HIV positive patients with 
lower CD4 counts were shown to have poorer prognosis with regards to survival. HIV status was 
not shown to be a risk factor for recurrence. The overall survival and disease-free period at 5 years 
was similar to that of other international studies. Only two thirds of the patients were adequately 
selected for surgery according to the institution’s criteria for a Wertheim’s hysterectomy and 
therefore it may be necessary to reconsider the pre-operative assessment of these patients. More 
advanced stages, tumours ≥ 4cm, adenomatous cell type, poor differentiation, > 5mm depth of 
invasion, >7mm lateral spread, higher number of nodes positive for metastatic disease, surgical 
margins  10mm, positive lympohovascular space, parametrial and pouch of Douglas involvement 
were factors that had a poorer prognosis with regards to recurrence, overall survival and disease-
free interval. However, the rates of recurrence were not statistically significant at a 95% 
confidence level.  
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1. INTRODUCTION 
Cervical cancer is the 3
rd
 most common female malignancy globally but it is commonest cancer in 
the developing world. The worldwide burden of disease (85%) and mortality from disease (88%) is 
therefore primarily in developing countries. In 2008 the global mortality:incidence ratio of cervical 
cancer was 52%, accounting for 270000 deaths.
 1 
 
 
Cancer of the uterine cervix is classified according to the internationally recognised FIGO 
Committee on Gynaecology Oncology classification of 2009. 
2  
Table 1: FIGO classification of Carcinoma of the Cervix Uteri 2009 
Stage I Carcinoma confined to cervix  
IA Invasive carcinoma diagnosed microscopically, with depth ≤5.0 mm and extension ≤7.0 mm 
IA1 Measured stromal invasion of ≤3.0 mm in depth and horizontal extension of ≤7.0 mm 
IA2 Measured stromal invasion of >3.0 mm and not >5.0 mm with an extension of not >7.0 mm 
IB Clinically visible lesions limited to cervix or pre-clinical cancers greater than stage IA  
IB1 Clinically visible lesion ≤4.0 cm in greatest dimension 
IB2 Clinically visible lesion >4.0 cm in greatest dimension 
Stage II Cervical carcinoma invades beyond uterus, but not to pelvic wall or to lower third of the vagina 
IIA Without parametrial invasion 
IIAl Clinically visible lesion ≤4.0 cm in greatest dimension 
IIA2 Clinically visible lesion >4.0 cm in greatest dimension 
IIB With obvious parametrial invasion 
Stage III The tumour extends to pelvic wall and/or involves lower third of vagina and/or causes 
hydronephrosis or non-functioning kidney  
IIIA Tumour involves lower third of the vagina, with no extension to the pelvic wall 
IIIB Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney 
Stage IV The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of 
the bladder or rectum. A bullous oedema, as such, does not permit a case to be allotted to Stage IV 
IVA Spread of the growth to adjacent organs 
IVB Spread to distant organs 
 All macroscopically visible lesions–even with superficial Invasion–are allotted to stage IB carcinomas. 
Invasion is limited to a measured stromal invasion with a maximal depth of 5.0 mm and a horizontal extension 
of not >7.0 mm. Depth of invasion should not be >5.0 mm taken from the base of the epithelium of the 
original tissue–superficial or glandular. The depth of invasion should always be reported in mm, even in those 
  2  
cases with “early (minimal) stromal invasion” (~1.0 mm). The involvement of vascular/lymphatic spaces 
should not change the stage allotment. 
 On rectal examination, no cancer-free space between the tumour and the pelvic wall. All cases with 
hydronephrosis or non-functioning kidney are included, unless they are known to be due to another cause. 
2
 
 
Stage specific treatment of the above-mentioned stages is tailored according to prognosis and risk 
of recurrence as determined by tumour type, tumour size, tumour grade, lymph node metastases, 
lymphovascular space involvement (LVSI), parametrial spread and presence of any other distant 
metastatic deposits which correlate with outcomes in numerous studies.
3 
  
Within our institution only the following treatment options are practised: 
 Stage IA1 is treated with simple hysterectomy if childbearing is complete or by cervical 
conisation if childbearing is incomplete. Stage IA1 with LVSI is managed by modified 
radical hysterectomy and pelvic lymphadenectomy.  
 Stage IA2 is managed by a simple hysterectomy and pelvic lymphadenectomy.  
 Stage IB1 and some Stage IB2 are managed with radical hysterectomy and pelvic 
lymphadenectomy. 
 Bulky Stage IB2 and Stage IIA2 treatment is chemo radiation only. 
 Stages IIB to IVA are managed with chemo radiation only. Patients with IVA lesions and a 
fistula are candidates for pelvic exenteration. 
 Stage IVB management is palliative chemotherapy and or palliative radiotherapy or 
supportive care i.e. pain control and hospice. 
4, 5
 Even though radical trachelectomy and 
pelvic lymphadenectomy is recommended for select patients with Stage IA1 with LVSI, 
Stage IA2 and even Stage IB1 who desire to maintain fertility, this modality has not been 
practised in our institution.   
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2. LITERATURE REVIEW 
 
For Stage IB squamous carcinoma lesions of the cervix, early studies done between 1970 and 1990 
indicated that the 5 year survival rates were 80 to 90% if either radical hysterectomy with pelvic 
lymph-adenectomy or if radical radiation therapy were used as primary therapy. In these studies 
rates of major complications were low with either of these therapeutic techniques. 
6, 7
 Later studies 
done in 2009 showed that risk of death was 59% lower in patients treated primarily with surgery 
versus radiotherapy (RT). 
8
 Therefore primary surgery was then recommended over primary RT for 
the management of these lesions. 
 
Recurrence rates however were higher and survival rates were lower in patients treated surgically if 
lymph nodes, parametria and surgical margins were involved and if patients had large or deeply 
invasive lesions. In these cases, adjuvant radiotherapy or chemo-radiotherapy (CRT) was required 
to reduce recurrences and improve survival. CRT decreases recurrences and improves survival more 
than RT alone (80% versus 63%). 
9 
Hysterectomies are classified into: Class I, Class II, Class III and Class IV. 
10
 
Class I hysterectomy is aimed at removal of all cervical tissue only. 
Class II, is aimed at removal of more para cervical tissue, but preserves distal ureteric and bladder 
blood supply. The upper third of the vagina and medial half of the cardinal ligaments are removed. 
Class III hysterectomy entails radical excision of parametrial and paravaginal tissues, as well as 
pelvic lymphadenectomy. Uterine arteries are ligated at their origin from the internal iliac arteries. 
Uterosacral ligaments are resected at their sacral attachments and cardinal ligaments are excised at 
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the pelvic wall. Half of the vagina is excised. The ureter is dissected from the pubo-cervical 
ligament almost completely but the superior vesicle artery is spared thereby preserving some of the 
distal ureteric blood supply.  
Class IV hysterectomy is aimed at complete removal of all peri-urethral tissue, more extensive 
excision of the peri-vaginal tissue and internal iliac vessel excision at the pelvic wall if necessary. 
The superior vesicle artery blood supply is lost as the ureter is completely excised off the pubo-
vesicle ligament and three quarters of the vagina is removed. A more extensive lateral dissection is 
done if metastases occupy the parametrium. 
10 
 
At our institution, Class III or Meig’s Radical hysterectomy/Wertheim’s hysterectomy and bilateral 
pelvic lymphadenectomy is recommended for patients with Stage IB1 and most patients with IB2 
tumours. These patients must have a good functional status as defined by the WHO / European 
Cooperative Oncology Group (ECOG) Performance Status Scoring System, they must be medically 
fit for surgery, under 65 years of age and should weigh  85kgs. Ovaries are conserved in pre-
menopausal patients younger than 45 years of age. 
11
 Pre-operatively patients with clinically 
significant lymphadenopathy do not qualify for Wertheim’s hysterectomy, but if intra-operatively 
enlarged or clinically suspicious nodes detected, surgery should be completed. 
11
  
Histological findings post-operatively play a significant role in determining further management. 
Surgical margins must be 10mm clear of tumour with no positive lymph nodes or tumour deposits 
in parametria or POD, otherwise external beam radiotherapy and vaginal vault intra-cavitary 
brachytherapy with or without adjuvant chemotherapy is recommended in addition to primary 
surgical management.  
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Patients’ with a poor functional status, clinically significant lymph nodes and or significant vaginal 
involvement do not qualify for surgical intervention but are treated with CRT only. Post-operative 
external beam radiation uses a 4 field pelvic box technique administering 48Gy of high energy 
photons in 24 daily fractions. Four separate fields are used (opposed anterior-posterior beams and 
opposed lateral fields). Each field is shaped shielding as much of the surrounding normal tissues as 
possible especially the small intestines and rectum. Concurrent chemotherapy is used in our 
institution if the patient has 2 or more risk factors. Risk factors include LVSI, multiple positive 
pelvic nodes, positive margins or tumour deposits seen in parametria or POD. Cis-platinum is given 
once weekly for three weeks. Positive or close margins are boosted with 15Gy vaginal ovoid 
brachytherapy in 3 divided doses 4 to 6 weeks after external beam radiotherapy or reduced external 
beam field ports to a dose of 60-65Gy are used. 
11 
In our institution brachytherapy is administered 
by a tandem and ovoid applicator inserted intra-vaginally under anaesthesia. 
Internationally Stage IB disease is managed surgically in the same way as it is in our institution. 
Patients with significant lymphadenopathy are also excluded from surgery. Post-operative 
management however is then decided by classifying patients as intermediate risk or high risk. 
Sedlis’ criteria are used to classify women as intermediate risk and Peters’ criteria are used to 
classify women as high risk. 
        
INTERMEDIATE RISK (Sedlis’ Criteria) 12 
1. LVSI plus deep 1/3 cervical stromal invasion in any size tumour. 
2. LVSI plus middle 1/3 cervical stromal invasion in ≥ 2cm tumour. 
3. LVSI plus superficial 1/3 cervical stromal invasion ≥ 5cm tumour. 
4. No LVSI but middle or deep 1/3 cervical in ≥ 4cm tumour. 
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Recurrence risk and death if the above risk factors are present is about 30% after surgery. 
12 
In these 
patients only adjuvant RT is recommended as although adjuvant CRT improves recurrence risk, no 
difference was shown in overall survival. 
13 
HIGH RISK (Peters’ Criteria) 9, 14 
1. Positive surgical margins 
2. Pathological parametrial involvement 
3. Positive pelvic nodes  
Recurrence risk is 40% and risk of death 50% with the above risk factors.
 9, 14
 Adjuvant CRT is 
therefore advocated internationally for these high-risk patients.  
Aside from the controversy of whether patients with Stage IB should be treated with RT alone or 
with CRT post-operatively, a study by Rose PG et al also looked at outcomes when two 
chemotherapeutic agents were used as opposed to one. Hydroxyurea, 5- Fluorouracil and Cisplatin 
alone or in combination were assessed in advanced cervical cancer. Cisplatin alone or in 
combination was superior to the other agents. 
3
 
Peters et al. compared outcomes of high risk patients treated postoperatively with RT alone to CRT 
(Cisplatin and 5-Fluorouracil). Results showed that CRT was more effective for progression free 
survival at 4 years (80% versus 63%) and overall survival at 4 years (81% versus 71%) but caused 
more serious toxicity, namely: Neutropenia (35 versus 3 cases), Leukopenia (40 versus 1 case), 
Nausea (17 versus 2), Vomiting (15 versus 2) compared to RT alone.  
In light of the toxicity risk, single-agent platinum based CRT is more often recommended 
internationally because it still significantly increases overall survival, and reduces progression and 
  7  
recurrence rates compared to RT alone, even in high risk patients. 
3
 In our institution we offer only 
single agent cisplatin chemotherapy with the irradiation.  
Anecdotal evidence suggests that patients in our institution should have good outcomes as we are 
highly selective by only managing Stage IB1 patients surgically and then with adjuvant RT or CRT 
whereas internationally Stage IB1, some IB2 and some IIA are managed in this way. Since tumour 
size and depth of invasion are independent risk factors for higher rates of recurrence and lower 
disease-free survival time it would seem that we should have good outcomes if patients were 
adequately selected.  
A study by Landoni et al assessed intra-operative, early and late complications associated with 
Class III hysterectomies. Four percent of the patients developed intra-operative and early adverse 
outcomes and complications including obturator nerve resection, ureteric resection, uterine artery 
haemorrhage, haematomas, uterovaginal fistulae, pulmonary emboli, deep vein thromboses and 
wound abscess. Late complications occurred in 38% of cases and complications included abdominal 
hernia, wound infection, ileus, lower limb oedema, lymphocysts, hydroureteronephrosis, stress 
incontinence, atonic bladder and low compliance bladder. Patients who then received RT post 
operatively had a cumulative complication rate of 45%. 
15  
HIV positive women have a five to eight-fold higher risk of cervical cancer compared to HIV 
negative women. 
16
 HIV positive women with invasive cervical cancer also tend to have lower CD4 
counts and higher viral loads than those without cervical cancer and present about 10 years earlier 
with more advanced disease. 
17, 18 
Patho-physiologically the HIV-encoded Tat protein enhances the 
expression of HPV associated oncogenesis. 
19 
Radical hysterectomy is also used for tumours up to 
and including stage IIA in HIV positive asymptomatic patients without any significant increase in 
overall morbidity relative to HIV positive women. 
20 
Postoperative CRT is also used for women at 
  8  
increased risk of recurrent or persistent disease but recovery from myelosuppression may be slower 
than in HIV-negative women. 
16 
A cervical carcinoma cohort of stages IB1-IB2 followed up over 9 years following radical surgery 
with or without radiotherapy showed that 5-year progression-free survival rates for surgery-alone 
and surgery with RT groups were 93% and 90% and overall survival rates were 96% and 91% 
respectively. 
21 
 
Problem Statement 
The type and frequency of complications after Wertheim’s hysterectomy with or without adjuvant 
therapy had never been assessed at our institution and this study attempted to quantify and assess 
our complications. In addition, the recurrence risk differences between HIV positive and negative 
women was also analysed.  Our study assessed disease free interval and overall survival in our 
institution at a minimum of 2 years post-operatively depending on the date of surgery. 
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3. AIM 
The primary aim of this study was to assess disease free interval and overall survival of those 
patients who presented with Stage IB1 cervical cancer and had a radical hysterectomy and pelvic 
lymphadenectomy as their primary modality of treatment irrespective of whether they received 
adjuvant CRT or not. Secondary aims were to assess the adequacy of selection, recurrence rate, 
prognostic factors causing high rates of recurrence, morbidity, mortality and complications in 
patients with Stage IB1 post Wertheim’s hysterectomy alone or with further management namely 
adjuvant radiotherapy or chemo-radiotherapy.  
 
4. OBJECTIVES 
The purpose of this study was to:  
4.1. Primary  
1. Assess the disease-free interval and overall survival in our institution at 2 years post-
operatively. 
4.2. Secondary  
1. Assess the adequacy of patient selection for Wertheim hysterectomy in view of correlation 
between pre-operative clinical staging and post-operative histological staging. 
2. Determine risk factors for recurrence. 
3. Quantify increases in recurrence risk of HIV positive patients versus HIV negative patients. 
4. Determine surgical and post-surgical complication rate. 
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5. METHODS 
 
5.1. Setting 
Charlotte Maxeke Johannesburg Academic Hospital is a tertiary/quaternary hospital associated 
with the University of the Witwatersrand, Faculty of Health Sciences. The hospital offers a full 
range of secondary, tertiary and quaternary (highly specialised) services. The hospital offers 
services to the population of Gauteng province and neighbouring provinces. Patients are also 
referred from other clinics, primary, secondary and tertiary hospitals that may not provide all the 
services available at Charlotte Maxeke Johannesburg Academic Hospital. Costs of patient 
treatment are funded by a National Tertiary Services Grant, as well as Provincial allocation. The 
hospital also serves many patients from other African countries that are usually self-referrals and 
who feel the health service in their countries is inadequate.  
 
5.2. Study population 
At our institution, all patients with cervical cancer are presented at a combined 
gynaecology/oncology clinic once every week. Clinical findings in conjunction with histological 
findings are used to determine management strategy. At this meeting, potential candidates for 
Wertheim’s hysterectomy are assessed by a senior gynaecologist or subspecialist. Patients 
included in the study were clinically staged as either IB1 or IB2 and fulfilled all pre-operative 
requirements for management by Wertheim’s hysterectomy with regards to age, ECOG status, 
tumour size, tumour type and confinement to cervix. 
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The ECOG Performance Status Scoring System of criteria is used by doctors & researchers to 
assess patients’ disease progression, how disease affects daily living abilities, and to determine 
appropriate treatment and prognosis. (See Table 2) 
 
Table 2: ECOG Performance Status Scoring System 
Score Description 
0 Asymptomatic (Fully active, able to carry on all pre-disease activities without restriction) 
1 Symptomatic but completely ambulatory (Restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or sedentary nature. For example, light 
housework, office work) 
2 Symptomatic, <50% in bed during the day (Ambulatory and capable of all self-care but 
unable to carry out any work activities. Up and about more than 50% of waking hours) 
3 Symptomatic, >50% in bed, but not bed bound (Capable of only limited self-care, confined 
to bed or chair 50% or more of waking hours) 
4 Bed bound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or 
chair) 
5 Death   
Positive Margins = tumour present at or within 1mm of the inked margin of resection. 
Negative Margins = no tumour within 1 cm of the inked margin. 
 
5.2.1. Inclusion criteria 
All the patients who had a Wertheim’s hysterectomy at Charlotte Maxeke Johannesburg 
Academic Hospital for Stage IB1 and 1B2 cervical cancer were included. 
 
5.2.2. Exclusion criteria 
Patients with any stage not managed by Wertheim’s hysterectomy 
 
5.3. Study design 
This was a retrospective cohort record review of all Wertheim Hysterectomies for cervical 
cancer Stages IB1 or IB2 done between the 1
st
 of January 2002 and the 31
st
 of December 2012. 
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5.4. Data collection 
Names and hospital numbers of the patients and dates of their surgeries were collected from the 
gynaecology theatre record books. All cases treated between 2002 and 2012 were included. 
Names and hospital numbers were then used to access patients’ admission and surgical records. 
From these records, we noted the following variables:  
 duration of surgery,  
 intra-operative complications, 
 number of blood products required, as well as  
 immediate post-operative recovery and complications. 
 
The National Health Laboratory Services (NHLS) database post-operative histology reports were 
accessed and all histological parameters documented. These included the:  
 tumour cell type,  
 grade, depth of invasion, and lateral spread, 
 LVSI, and  
 POD and parametrial involvement.  
 Positive margins were noted if tumour was present at or within 1mm of the inked margin 
of resection. 
 Negative margins were noted if no tumour was present within 1 cm of the inked margin 
of resection. 
 
Histological stage and number of positive pelvic lymph nodes removed were also noted. 
 
We accessed radiation-oncology clinic files for further management post-operatively as 
determined by histology findings. Patients either received no further management, or radiation or 
chemo-radiotherapy depending on the risk category within the stage of disease. 
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We then accessed these patients’ gynaecology outpatient files. Both these and the radiation 
oncology files were used to note post-operative follow up and cervical smears, as well as to 
determine disease free interval, overall survival and recurrence rates. Where patients had not 
followed up within the last 3 months of data collection – they were contacted telephonically or at 
home addresses supplied in these files. For patients who had not followed up within the last 3 
months of data collection and could not be contacted telephonically or at home addresses we 
requested that the department of home affairs check if their deaths had been registered. 
 
5.5. Data analysis 
This was a retrospective institutional cohort study. Relevant patient information was collected on 
a patient information sheet. These details were then entered into a Microsoft Excel datasheet, and 
analysed statistically. Categorical data was summarized using frequencies, percentages and 
cross-tabulations, while continuous data was summarized using means, standard deviation and 
ranges. 
For the primary objective, disease free interval and overall survival were expressed as means 
with 95% confidence intervals using the Kaplan Meyer test. 
For the secondary objectives, Fischer’s exact test was employed. Statistical significance was set 
at p < 0.05. 
 
5.6. Ethics Approval 
Application for ethics was granted by the Wits Ethics Committee. Informed consent was not 
required since the study was based on record reviews and did not interfere with patient 
management. Each patient’s data was entered under a subject number and no names or hospital 
numbers were used in the final statistical analysis to ensure confidentiality of individual patients. 
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All data was represented as aggregates thereby guaranteeing the confidentiality of individual 
patients.  
 
5.7. Timing  
The study included data from the files of all Wertheim’s hysterectomies done at Charlotte 
Maxeke Johannesburg Academic Hospital for Stage IB1 cervical cancer from the 1
ST 
January 
2002 to 31
st 
December 2012. The study also included data from the same patients’ files of 
subsequent postoperative visits, both gynaecological, radiation oncology and medical oncology. 
 
5.8. Funding 
The primary costs in the study were stationery and telephone calls for patient follow up which 
the researcher funded herself. 
 
5.9. Permission from institution 
Permission to do the study and to access patient’s files with surgical, cytological and histological 
data was requested and granted from the superintendent Ms Bogoshi as well as clinical heads of 
departments of Obstetrics and Gynaecology, Prof F. Guidozzi, Radiation Oncology, Prof V. 
Sharma and Anatomical Pathology / NHLS, Prof MJ Hale. Copies of the approval letters are 
included in the appendix. Access to patient files with follow up information post-surgery, 
radiotherapy or radio/chemotherapy was also requested. 
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6. RESULTS 
 
Initially 72 patients were identified for the study from the theatre case records as having had either 
radical hysterectomy or Wertheim’s hysterectomy with pelvic lymphadenectomy. These were all 
Class III Meigs hysterectomies according to the Piver-Rutledge-Smith classification. Two were 
excluded as they were endometrial carcinomas and not cervical carcinomas. One was excluded 
because the procedure was abandoned when a lymph node removed intra-operatively showed 
metastatic disease on frozen section and therefore 69 patients were therefore included in the study. 
  
6.1. Demographic profile of patients 
6.1.1. Age distribution 
The mean age of the study population was 45 years of age. The distribution of cases performed 
per age group is shown in Figure 1 below. 
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Figure 1: Distribution of cases performed per age group 
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6.1.2. Race profile  
The racial distribution of patients is represented in the pie chart below. The majority of the 
patients were Black 47 (68.12%), followed by White 18 (26.09%), then Coloured 2 (2.9%) and 
Indian 2 (2.9%). (See Figure 2) 
 
 
Figure 2: Race distribution of Patients 
 
6.1.3. Parity and Gravidity 
The average parity for the patients included in the study who were alive was 2.86 and that of 
those who were deceased at the end of the study was 2.5. At the end of the study, the average 
gravidity was 3.56 for patients who were alive and 2.8 for those who had died.  
47
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6.1.4. HIV status and CD4 count 
Forty (58%) of the patients in the study were HIV seronegative, 24 (35%) were HIV 
seropositive and the status of 5 (7%) of the patients was unknown. (See Figure 3) 
 
 
 
The distribution of the CD4 counts of the HIV reactive is shown in Figure 4. 
 
Figure 4: The distribution of the CD4 counts of the HIV reactive patients 
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Figure 3: Distribution of Patients by HIV status 
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6.1.5. ECOG Performance Status 
The majority of patients in the study were ECOG performance status 1 i.e. symptomatic and 
100% ambulatory 57 (83%). 11 (16%) were ECOG performance status 0 i.e. Asymptomatic 
and 1 (1%) was ECOG performance status 2 i.e. Symptomatic > 50%ambulatory. The most 
common symptom that patients presented with was a foul-smelling vaginal discharge. (See 
Table 3) 
 
Table 3: Distribution of Patients by ECOG Performance Status 
ECOG Performance Status No. of patients 
Asymptomatic 11 
Symptomatic and 100% ambulatory 57 
Symptomatic > 50% ambulatory 1 
Symptomatic < 50% ambulatory 0 
Bed bound 0 
Death 0 
Total 69 
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6.2. Disease free interval 
The primary objective of the study was to assess disease free interval and overall survival 2 
years post operatively. The figure below summarises the post-operative disease free periods 
experienced by patients in the study and the proportion of patients who experienced them. (See 
Figure 5) 
 
 
Figure 5: Proportion of patients split by number of Disease-free years post-operatively 
 
The average number of years disease free postoperatively was 5 years for patients included in 
the study, although 24 (35%) of the patients were disease free for more than five years.  
Analysing only the patients which were in the study for more than 5 years increases the average 
number of disease free years to six years. 
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6.3. Survival Analysis 
The overall survival at 30 June 2015 showed that 59 (86%) of the patients were alive and 10 
(14%) were deceased.  Of the 10 cases that demised: 
 Five were due to local recurrence and cause of death was renal failure;  
 One was due to metastatic disease initially identified in the liver.  
 Two of the patients who died had squamous cell tumours of the oesophagus. One of these 
initially had an adenoid basaloid cervical carcinoma and the other one initially had a 
squamous cell cervical carcinoma.  
 One was due to an HIV-associated illness according to a family member 
 One cause of death was unknown as all available contact details were no longer in 
service and the patient’s family no longer lived at given address. The department of home 
affairs was only willing to furnish us with this patient’s date of death but not the cause of 
death. (See Figure 6) 
 
 
 
Survival analysis of patients by HIV status is covered in detail in Section 6.8 of this report. 
 
59 
Still Alive 
86% 
10 
Deceased 
14% 
    Survival Status at 30 June 2015 
Figure 6: Survival status of patients as at 30 June 2015 
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6.4. Kaplan Meier Analysis 
A brief synopsis of when patients died in the months following surgery and treatment clearly 
shows that death is unlikely up to 3 years postoperatively with or without adjuvant CRT. 
Approximately 30% of the study population was only followed up for less than 3 years beyond 
the cut-off point of the study and therefore their survival beyond 3 years is not included in this 
Kaplan Meier plot. (See Figure 7) 
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Figure 7: Survival Analysis by Duration since Treatment 
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Table 4: Survival probabilities by Duration 
       Table 5: Patients entering study by Year 
Year Number of 
patients 
Number of 
years in 
study 
2002 5 13 
2003 1 12 
2004 3 11 
2005 3 10 
2006 6 9 
2007 1 8 
2008 9 7 
2009 7 6 
2010 7 5 
2011 6 4 
2012 21 3 
2013 0 2 
2014 0 1 
 
 
The number of patients entering the study each year is shown in       Table 5. A much larger number 
of patients (21) entered the study in 2012 compared to previous years. An oncology fellow joined 
the group of surgeons in 2012. It is possible that the detection rate of resectable early stage cervical 
cancer increased for surgical teaching purposes in that year. Nineteen surgeries were performed by 
the team in 2012 which was significantly higher than the average of 2.6 surgeries per surgeon in the 
preceding years. This caused a distortion in the numbers as patient follow up for the study ended in 
30/06/2015 with a resultant drop in the numbers of patients after Year 3. 
Years since 
treatment 
Probability 
of survival 
Cumulative 
Probability 
of Survival 
0 100% 100% 
1 97% 97% 
2 99% 96% 
3 94% 90% 
4 68% 61% 
5 86% 52% 
6 81% 42% 
7 86% 36% 
8 72% 26% 
9 89% 23% 
10 69% 16% 
11 64% 10% 
12 71% 7% 
13 60% 4% 
14 33% 1% 
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6.5. Co-morbidities 
Survival was then assessed relative to co-morbidities to assess any trends or commonalities. 
 
Table 6: Co-morbidities by survival status 
Co-morbidities and Survival 
Status 
Still Alive Deceased 
Diabetes mellitus 2 1 
Epilepsy 2 0 
Asthma 1 0 
COPD 2 0 
Heart disease 0 1 
Hypertension 15 4 
Other 6 2 
Nil 38 5 
 28 8 
 
 Table 7: Number of co-morbidities and survival status 
Number of co-morbidities Still Alive Deceased 
0 38 5 
1 16 2 
2 3 3 
3 2 0 
Total 59 10 
   
Average 0.47 0.80 
 
Of  those who died 1 in 2 lived with co-morbidities compared to those alive, where about 1 in 3 
had co-morbidities. This may suggest an association of improved survival status for those 
without co-morbidities. Chi-squared testing at the 95% confidence level does not show definitive 
correlation between the existence of, and numbers of, co-morbidities, with survival status.  This 
is partly due to the low number of deaths in the study as well as some co-morbidities impacting 
mortality more than others, e.g. hypertension was the most common co-morbidity amongst the 
patients and can be medicinally controlled. 
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With regards to duration of disease free interval on overall survival, the Fisher exact test for 
significance at 95% confidence yielded a p-value of 0.00012 for overall survival at 2 years post-
operatively indicating a strong statistically significant relationship at 2 years post-operatively 
between the disease free interval and overall survival. 
 
6.6. Adequacy of Patient Selection 
A secondary objective of the study was to assess the adequacy of patient selection for Wertheim 
Hysterectomy. To determine this, we compared the preoperative clinical staging based on either 
initial clinical assessment of patients referred from other hospitals with histology results or from 
postoperative diagnostic histology in cases where abnormal cytology was used to initially 
investigate patients or from diagnostic histology where clinically suspicious IB1 lesions were 
suspected. Eight patients had less significant disease on postoperative histological assessment.  
These included: 
 Two patients had HGSIL on pap smears and squamous cell carcinomas on LLETZ 
biopsy 
 One patient had HGSIL on pap smear and adenoid basal cell carcinoma on LLETZ 
biopsy 
 One patient had HGSIL on pap smear and squamous cell carcinoma on cone biopsy 
 One patient had HGSIL suspicious for invasion on pap smear and squamous cell 
carcinoma on LLETZ biopsy 
 One patient had squamous carcinoma on pap smear and on cervical punch biopsy 
 One patient had squamous carcinoma on pap smear and on LLETZ biopsy 
 One patient had no pap smear results and adeno-squamous carcinoma on cervical 
punch biopsy 
 
If patients were adequately selected the clinical staging and histological staging should have 
been the same. However in 6 of the above-mentioned 8 cases, poor correlation between clinical 
and histological stage was probably due to the bulk of the tumour having been resected with the 
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initial histological diagnostic procedure i.e. LLETZ or cone biopsy. In 2 of the 8 cases, where 
diagnosis was based only on cervical punch biopsies, it is likely that incorrect clinical staging 
explains the discrepancy. The correct management in these 2 cases would then have been a 
simple hysterectomy. 
 
We found that the preoperative and postoperative stages correlated in 42 (61%) of the patients 
and these were therefore treated correctly. Overall preoperative and postoperative stages did 
not correlate in 27 (39%) of the patients. 
 
Four (6%) of the patients which were incorrectly assessed as IB1 preoperatively but were IB2 
postoperatively and therefore were also managed correctly since Wertheim’s Hysterectomy is 
the correct management for IB1 and IB2. 
 
Eight (12%) of the patients were staged as IB1 preoperatively but postoperatively had Stage IA1 
or Stage IA2 disease – these cases were therefore over treated based on postoperative histology 
but correctly treated based on preoperative histology and or clinical assessment. This brings the 
overall total of correctly managed patients to 52 (75%). 
 
Two (3%) of the above-mentioned 8 (12%) who were staged based on clinical assessment were 
not staged correctly and should have had a simple hysterectomy.  
Fifteen patients (22%) were staged as IB1/IB2 preoperatively but postoperatively 6 (9%) were 
IIA, 2 (3%) were IIB and 7 (10%) were IIIB.  
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This means a total of 17 (25 %) were incorrectly managed, as they should have either had a 
simple hysterectomy or not have been managed surgically but with radiation alone or chemo-
radiation as per our and international protocols.  
A summary of the results of the analysis is shown in the table below. (See Table 8) 
 
Table 8: Correlation between Pre-Operative Clinical stage & Post-Operative Histological Stage 
Count of patients by staging 
Preoperative Clinical Staging Preoperative Clinical Staging 
Postoperative Stage Stage IB1 Stage IB2 Stage IB1 Stage IB2 
NIL 2 0 
12% 
0% 
Stage IA1 3 0 
Stage IA2 3 0 
Stage IB1 42 0 61% 
Stage IB2  4 0 
25% 
0% 
Stage IIA 5 1 
2% 
Stage II B 2 0 
Stage IIIA 0 0 
Stage IIIB 6 1 
Stage IVA 0 0 
Stage IVB 0 0 
Total 67 2   
Key to colour coding 
 
 
Chi-squared testing was performed on the overall adequacy of patient selection compared against 
expectations of 80% correct management.  This showed statistically significant difference with 
expectation (p-value of 0.000005803) – i.e. inadequate patient selection. However, it cannot be 
definitively stated whether patient selection is more adequate for pre-operative staging for Stage 
IB1 or for Stage IB2 - given the low number of patients identified as IB2 at preoperative staging.    
 Over-treatment 
 Correct treatment 
 Incorrect treatment 
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6.7. Risk Factor Analysis 
Another secondary objective was to assess risk factors for recurrence.  Due to the low number of 
patients with recurrence (only 12 out of the total 69) the Fisher tests for recurrence by individual 
prognostic factors did not yield differences that are statistically significant.  There are however 
some strong trends observable from the prognostic factors for these patients. 
Each of these factors are analysed in turn in the sections below. 
 
6.7.1. Post-Operative Histology Cell Type 
Seventy percent of the cohort had squamous cell carcinomas, 15% had adenomatous cell 
carcinomas and 1% had other cell carcinomas. The latter was one patient that had a basal cell 
carcinoma (Figure 8). Probability of patients with adenomatous carcinoma who had either 
adenocarcinoma, adenoid basal or adeno-squamous carcinoma subtype had lower survival 90% 
versus squamous carcinoma subtype 96% at 2 years but had a higher disease-free period 90% 
compared to those with a squamous carcinoma subtype 83%. (Table 9) and (Table 11) 
respectively. (See Figure 8) 
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Figure 8: Distribution of Post-Operative Histology Cell Type 
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Table 9: Survival Period according to Post-Operative Histology Cell Type 
Post-Operative Histology 
Cell Type 
Number of 
patients 
surviving 
< 2 years 
Number of 
patients 
surviving 
≥ 2 years 
Total number 
of patients 
Probability of 
survival 
period ≥ 2 
years 
Adenomatous cell carcinoma 1 9 10 90% 
Nil 0 10 10 100% 
Other cell carcinoma 0 1 1 100% 
Squamous cell carcinoma 2 46 48 96% 
Aggregate 3 66 69 96% 
 
Survival periods by Postoperative Histology Cell Type do not differ significantly at the 95% 
level confidence level. (See Table 9) 
  
Table 10: Recurrence rates according to Post-Operative Histology Cell Type 
Postoperative  Histology Cell 
Type 
Non-Recur Recur Total 
Adenomatous Cell Carcinoma 10 0 10 
Nil 10 0 10 
Other Cell Carcinoma 1 0 1 
Squamous Cell Carcinoma 36 12 48 
 
Recurrence rates by Postoperative Histology Cell Type do not differ significantly at the 95% 
level confidence level.  However, it is worth noting that all patients who had recurrence also 
had squamous cell carcinoma. (See Table 10)  
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Table 11: Disease Free Period according to Post-operative Histology Cell Type 
Post-Operative Histology 
Cell Type 
Number of 
patients with 
disease free 
period 
< 2 years 
Number of 
patients with 
disease free 
period 
≥ 2 years 
Total number 
of patients 
Probability of 
disease free 
period ≥ 2 
years 
Adenomatous Cell Carcinoma 1 9 10 90% 
Nil 0 10 10 100% 
Other Cell Carcinoma 0 1 1 100% 
Squamous Cell Carcinoma 8 40 48 83% 
Grand Total 9 60 69 87% 
 
 
 
6.7.2. Postoperative stages 
Three of the 5 patients who died of recurrence had more advanced postoperative stages than 
Stage IB1/IB2 – 1 was Stage IIA and 2 were Stage IIIB. All 5 had positive margins and 3 had 
nodes which were positive for metastatic disease.  
As expected our study data shows that the probability of surviving and being disease free for 
more than 2 years is highest for no residual tumour present after initial diagnostic procedure for 
histology 100% and 100% respectively. 
Probability of survival at 2 years was higher for stage I at 96% and Stage II at 100% compared 
to Stage III at 86%. Probability of being disease free for more than 2 years was highest for 
Stage I at 94%, followed by Stage II at 63%, and lowest for Stage III at 57%. We can infer 
from these results that patients with Stage I and II disease are more likely to be alive and 
disease free at 2 years or more compared to those with Stage III disease. (See Figure 9) 
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The influence of the Stage on the survival period is shown below in Table 12. 
 
Table 12: Survival Period according to Post-operative Stage 
Postoperative stage Number of 
patients 
surviving 
< 2 years 
Number of 
patients 
surviving 
≥ 2 years 
Total number 
of patients 
Probability of 
survival 
period ≥ 2 
years  
Nil 0 2 2 100% 
Stage I 2 50 52 96% 
Stage II 0 8 8 100% 
Stage III 1 6 7 86% 
Grand total 3 66 69 96% 
 
 
The influence of the Stage on the disease-free period is shown in Table 13. 
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Figure 9: Distribution of patients according to Stage 
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Table 13: Disease Free Period according to Stage 
Postoperative stage Number 
of patients 
with 
disease 
free 
period 
< 2 years 
Number 
of patients 
with 
disease 
free 
period 
≥ 2 years 
Total 
number of 
patients 
Probabilit
y of 
disease 
free 
period ≥ 2 
years 
Nil 0 2 2 100% 
Stage I 3 49 52 94% 
Stage II 3 5 8 63% 
Stage III 3 4 7 57% 
Grand total 9 60 69 87% 
 
Postoperative stage did not have a statistically significant impact on the 2 year Disease Free 
Period or 2 year Survival Period at 95% confidence level. 
 
6.7.3. Tumour Grade 
With regards to tumour grade as a risk factor for recurrence, 80% of the patients included in the 
study had moderately differentiated tumors’ on histology. The patients’ with poorly 
differentiated tumours had the highest probability of surviving (100%) and second highest 
probability (86%) of being disease free at 2 years or more. This is not in keeping with the fact 
that poorly differentiated tumours are more aggressive but is likely due to a relatively smaller 
number of patients in this category and the short follow up period of the study. Well 
differentiated tumours are the least aggressive but this has not been shown in this study since 
there was only a 50% probability of patients with this grade surviving and being disease free at 
2 years or more, this can however be explained by the fact that results may be skewed owing to 
the small number of patients which fell into the well differentiated category.  
Patients with moderately differentiated tumours (88%) were more likely to be disease free at 2 
years or more compared to those with well differentiated tumours (50%). Patients with 
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moderately differentiated tumours were also more likely to survive at 2 years or more (97%) 
compared to patients with well differentiated tumours (50%).  
The influence of the tumour grade on the survival and disease free period is shown in the tables 
below. (See Tables 14 and 15) 
 
Table 14: Survival Period according to Tumour Grade 
Tumour Grade Number of 
patients 
surviving 
< 2 years 
Number of 
patients 
surviving 
≥ 2 years 
Total number 
of patients 
Probability of 
survival 
period ≥ 2 
years 
Moderately Differentiated 2 58 60 97% 
Poorly Differentiated 0 7 7 100% 
Well Differentiated 1 1 2 50% 
Grand Total 3 66 69 96% 
 
 
Table 15: Disease Free Period according to Tumour Grade 
Tumour Grade Number of 
patients with 
disease free 
period 
< 2 years 
Number of 
patients with 
disease free 
period 
≥ 2 years 
Total number 
of patients 
Probability of 
disease free 
period ≥ 2 
years 
Moderately Differentiated 7 53 60 88% 
Poorly Differentiated 1 6 7 86% 
Well Differentiated 1 1 2 50% 
Grand Total 9 60 69 87% 
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Recurrence rates over the entire study period by tumour grade do not differ significantly at the 
95% confidence level.  
Ten out of the 12 patients that had recurrence had moderately differentiated tumours – (20%) 
recurrence for this tumour grade. Two of the 5 poorly differentiated tumours recurred – (40%) 
for this tumour grade. Neither of the 2 well differentiated recurred. This suggests in this study 
that tumour grade is more likely to give an indication of recurrence but not survival and disease 
free period with the disease. (See Table 16) 
 
Table 16: Recurrence rates by Tumour Grade 
Tumour Grade Non-Recur Recur Total 
Moderately Differentiated 50 10 60 
Poorly Differentiated 5 2 7 
Well Differentiated 2 0 2 
Total 57 12 69 
 
 
6.7.4. Tumour size 
Six percent of the patients in the study had tumours more than 4cm in size and 94% had 
tumours less than or equal to 4cm in size.  The influence of tumour size on survival period and 
disease-free period can be seen in the tables below. (See Tables 17 and 18) 
 
Table 17: Survival Period according to Tumour Size 
Tumour Size Number of 
patients 
surviving 
< 2 years 
Number of 
patients 
surviving 
≥ 2 years 
Total number 
of patients 
Probability of 
survival 
period ≥ 2 
years 
> 4CM 1 3 4 75% 
≤ 4CM 2 63 65 97% 
Grand Total 3 66 69 96% 
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Table 18: Disease Free Period according to Tumour Size 
Tumour Size Number of 
patients with 
disease free 
period 
< 2 years 
Number of 
patients with 
disease free 
period 
≥ 2 years 
Total number 
of patients 
Probability of 
disease free 
period ≥ 2 
years 
> 4CM 1 3 4 75% 
≤ 4CM 8 57 65 88% 
Grand Total 9 60 69 87% 
 
The patients in our study who had tumours more than 4cm in size had a lower probability of 
survival (75%) and of being disease free (75%) at 2 or more years compared to those who had 
tumours 4cm and less in size who had a 97% probability of survival and an 88% probability of 
being disease free at 2 years or more. 
 
The table below shows the recurrence rates by size of the tumour. 
Table 19: Recurrence rates by Tumour Size 
Tumour Size Non-Recur Recur Total 
> 4CM 4 0 4 
≤ 4CM 53 12 65 
Total 57 12 69 
 
Recurrence rates by tumour size do not differ significantly at the 95% level confidence level.  
However, worth noting is that all patients that had recurrence had tumour size ≤ 4cm.  
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6.7.5. Tumour Depth of Invasion 
Patients who had tumours with a depth of invasion less than or equal to 3 mm, as well as those 
with tumours more than 3mm but less than 5 mm of depth had the highest probability (100%) 
of surviving and of being disease free (100%) at 2 years or more. Those who had tumours of 
more than 5mm in depth had a lower probability of survival 93% and a lower probability of 
being disease free 80% at 2 years or more.  
 
Figure 10: Distribution of Tumour Depth of Invasion 
 
The influence of tumour depth of invasion on survival period and disease-free period can be 
seen in the tables below. (See Tables 20 and 21) 
 
Table 20: Survival Period according to Tumour Depth of Invasion 
Tumour Depth of Invasion Number of 
patients 
surviving  
< 2 years 
Number of 
patients 
surviving  
≥ 2 years 
Total number 
of patients 
Probability of 
survival 
period ≥ 2 
years 
≤ 3MM 0 13 13 100% 
>3MM and < 5MM 0 11 11 100% 
> 5MM 3 42 45 93% 
Grand Total 3 66 69 96% 
13
≤ 3MM
19%
11
Between 3MM 
and 5MM
16%45
> 5MM
65%
Tumour Depth of Invasion
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Table 21: Disease Free Period according to Tumour Depth of Invasion 
Tumour Depth of Invasion 
Number of 
patients with 
disease free 
period 
< 2 years 
Number of 
patients with 
disease free 
period 
≥ 2 years 
Total number 
of patients 
Probability of 
disease free 
period ≥ 5 
years 
≤ 3MM 0 13 13 100% 
>3MM and < 5MM 0 11 11 100% 
> 5MM 9 36 45 80% 
Grand Total 9 60 69 87% 
 
Recurrence rates by tumour depth of invasion do not differ significantly at the 95% level 
confidence level.  The majority of the patients with recurrence (10 out of 12) had tumour depth 
of invasion >5mm. None of the patients with tumours 3mm or less in depth had recurrence. 
(See Table 22) 
 
Table 22: Recurrence rates according to Tumour Depth of Invasion 
Tumour Depth Of Invasion Non-Recur Recur Total 
≤ 3MM 13 0 13 
> 3MM and < 5MM 9 2 11 
> 5MM 35 10 45 
Total 57 12 69 
 
 
6.7.6. Tumour Lateral Spread 
Seventy percent of the patients had tumours that had lateral spread more than 7mm and 30% 
had tumours with lateral spread less than or equal to 7mm. 
Tumours that had spread laterally to less than or equal to 7mm had a 100% probability of 
survival and a 95% probability of being disease free at 2 years or more postoperatively and this 
was as expected much higher than tumours that had spread laterally more than 7mm where 
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probability of survival was 94% and probability of being disease free was 83% at 2 years or 
more post operatively.  
 
 
The influence of tumour lateral spread on survival period and disease-free period can be seen in 
the tables below. (See Tables 23 and 24) 
 
Table 23: Survival Period according to Tumour Lateral Spread 
Tumour Lateral Spread Number of 
patients 
surviving 
< 2 years 
Number of 
patients 
surviving 
≥ 2 years 
Total number 
of patients 
Probability of 
survival 
period ≥ 2 
years 
> 7MM 3 45 48 94% 
≤ 7MM 0 21 21 100% 
Grand Total 3 66 69 96% 
 
Table 24: Disease Free Period according to Tumour Lateral Spread 
Tumour Lateral Spread Number of 
patients with 
disease free 
period 
< 2 years 
Number of 
patients with 
disease free 
period 
≥ 2 years 
Total number 
of patients 
Probability of 
disease free 
period ≥ 2 
years 
> 7MM 8 40 48 83% 
≤ 7MM 1 20 21 95% 
Grand Total 9 60 69 87% 
 
30% 
70% 
Tumour Lateral Spread 
 7MM 
> 7MM 
Figure 11: Distribution of Tumour Lateral Spread 
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Recurrence rates by tumour lateral spread do not differ significantly at the 95% confidence level  
The majority of patients with recurrence (11 out of 12) had tumour lateral spread > 7MM. (See 
Table 25) 
Table 25: Recurrence rates by Tumour Lateral Spread 
Tumour Lateral Spread Non-Recur Recur Total 
> 7MM 37 11 48 
≤ 7MM 20 1 21 
Total 57 12 69 
 
6.7.7. Lymphovascular space involvement 
 
Seventy two percent of the patients had no lymphovascular space involvement. Twenty eight 
percent did have lymphovascular space invasion histologically. 
Patients with histology that showed presence of lymphovascular space invasion had lower 
probabilities of survival and being disease free 2 years postoperatively compared to those 
without lymphovascular space invasion 96% and 92% respectively as opposed to 95% and 74% 
respectively. (See Figure 12) 
 
 
50 
NO 
72% 
19 
YES 
28% 
    Lymphovascular Space Involvement 
Figure 12: Distribution of Lymphovascular Space Involvement 
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The influence of Lymphovascular Space Involvement on survival period and disease free 
period can be seen in tables 26 and 27 below. 
 
Table 26: Survival Period according to Lymphovascular Space Involvement 
Lymphovascular Space 
Involvement 
Number of 
patients 
surviving 
< 2 years 
Number of 
patients 
surviving 
≥ 2 years 
Total number 
of patients 
Probability of 
survival 
period ≥ 2 
years 
No 2 48 50 96% 
Yes 1 18 19 95% 
Grand Total 3 66 69 96% 
 
Table 27: Disease Free Period according to Lymphovascular Space Involvement 
Lymphovascular Space 
Involvement 
Number of 
patients with 
disease free 
period 
< 2 years 
Number of 
patients with 
disease free 
period 
≥ 2 years 
Total number 
of patients 
Probability of 
disease free 
period ≥ 2 
years 
No 4 46 50 92% 
Yes 5 14 19 74% 
Grand Total 9 60 69 87% 
Fisher tests performed on recurrence rates by Lymphovascular Space Involvement do not differ 
significantly at the 95% level of confidence. However at 2 or more years postoperatively relative 
to numbers in each group, 36% of the patients with lymphovascular space involvement had a 
recurrence as opposed 16% recurrence for those who did not have lymphovascular space 
involvement. (See Table 28) 
Table 28: Recurrence rates by Lymphovascular Space Involvement 
Lymphovascular Space 
Involvement 
Non-Recur Recur Total 
NO 43 7 50 
YES 14 5 19 
Total 57 12 69 
  40  
6.7.8. Number of positive lymph nodes 
Fifty-nine patients had no positive lymph nodes, three had 1 positive lymph node, four had 2, 
one had 3, one had 6 and one had 8 positive lymph nodes.  
The study generally showed very high probability rates of survival at 2 or more years 
postoperatively but the greater the number of positive nodes removed at radical hysterectomy 
the lower the probability of being disease free at 2 or more years postoperatively. Survival was 
97% where there were no positive nodes, 67% where there was 1 positive node and 100% for 2 
to 8 positive nodes. Probability of being disease free was 93% for no positive nodes, 67% for 1, 
50% for 2 and 0% for 3 and 8 positive nodes. The only result not in keeping with this trend was 
shown for one patient where 6 positive nodes were removed but the patient survived and was 
disease free for longer than 2 or more years post-operatively. Since this was only the case for 
one patient it cannot be deemed to be significant. 
 
The influence of Positive Lymph Nodes on survival period and disease-free period can be seen 
in the tables 29, 30 and 31. 
 
Table 29: Survival Period according to Number of Positive Lymph Nodes 
Number Of Positive Lymph 
Nodes 
Number of 
patients 
surviving 
< 2 years 
Number of 
patients 
surviving 
≥ 2 years 
Total number 
of patients 
Probability of 
survival 
period ≥ 2 
years 
0 2 57 59 97% 
1 1 2 3 67% 
2 0 4 4 100% 
3 0 1 1 100% 
6 0 1 1 100% 
8 0 1 1 100% 
Grand Total 3 66 69 96% 
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Table 30: Disease Free Period according to Number of Positive Lymph Nodes 
Number of Positive Lymph 
Nodes 
Number of 
patients with 
disease free 
period 
< 2 years 
Number of 
patients with 
disease free 
period 
≥ 2 years 
Total number 
of patients 
Probability of 
disease free 
period ≥ 2 
years 
0 4 55 59 93% 
1 1 2 3 67% 
2 2 2 4 50% 
3 1 0 1 0% 
6 0 1 1 100% 
8 1 0 1 0% 
Grand Total 9 60 69 87% 
 
Table 31: Recurrence rates by Number of Positive Lymph Nodes 
Number Of Positive Lymph 
Nodes 
Non-Recur Recur Total 
0 51 8 59 
1 3 0 3 
2 2 2 4 
3 0 1 1 
6 1 0 1 
8 0 1 1 
Total 57 12 69 
 
Recurrence rates by number of positive lymph nodes do not differ significantly at the 95% level 
of confidence. The majority of the patients with recurrence had no positive lymph nodes (8 out 
of 12 patients). 
6.7.9. Parametrial Involvement 
Ninety four percent of the patients had no parametrial involvement and 6% did have 
parametrial involvement. In patients with parametrial involvement the survival probability was 
100% as opposed to 95% in those without involvement at 2 years or more. However the inverse 
was noted with regards to probability of remaining disease free at 2 years or more.  Only 50% 
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of those with parametrial involvement were disease free compared to 89% of those without 
parametrial involvement.  
The influence of Parametrial Involvement on survival and disease-free period is shown below. 
(See Tables 32, 33 and 34) 
 
Table 32: Survival Period according to Parametrial Involvement 
Parametrial Involvement Number of 
patients 
surviving 
< 2 years 
Number of 
patients 
surviving 
≥ 2years 
Total number 
of patients 
Probability of 
survival 
period ≥ 2 
years 
No 3 62 65 95% 
Yes 0 4 4 100% 
Grand total 3 66 69 96% 
 
Table 33: Disease Free Period according to Parametrial Involvement 
Parametrial Involvement Number of 
patients with 
disease free 
period 
< 2 years 
Number of 
patients with 
disease free 
period 
≥ 2 years 
Total number 
of patients 
Probability of 
disease free 
period ≥ 2 
years 
No 7 58 65 89% 
Yes 2 2 4 50% 
Grand Total 9 60 69 87% 
 
 
Table 34: Recurrence rates by Parametrial Involvement 
Parametrial Involvement Non-Recur Recur Total 
No 55 10 65 
Yes 2 2 4 
Total 57 12 69 
 
Recurrence rates by parametrial involvement do not differ significantly at the 95% confidence 
level.  However, worth noting was that 10 out of the 12 patients with recurrence did not have 
parametrial involvement. 
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6.7.10. Pouch of Douglas Involvement 
Seven percent (5) of the patients had Pouch of Douglas involvement and 93% (64) had no 
Pouch of Douglas involvement. 
In patients where the pouch of Douglas was involved probability of survival at 2 years or more 
was slightly higher at 100% as opposed to 95% when there was no involvement which   has 
been shown in previous studies but a relatively very small number of patients fell into the 
category where there was involvement and this is also therefore unlikely to be significant. 
Patients with pouch of Douglas involvement did have a marginally lower probability of being 
disease free after 2 years compared with those that did not have involvement – 80% as opposed 
to 88%.  
The influence of Pouch of Douglas Involvement on survival period and disease-free period can 
be seen in the tables below. (See Tables 35, 36 and 37) 
 
Table 35: Survival Period according to Pouch of Douglas Involvement 
Pouch of Douglas 
Involvement 
Number of 
patients 
surviving 
< 2 years 
Number of 
patients 
surviving 
≥ 2 years 
Total number 
of patients 
Probability of 
survival 
period ≥ 2 
years 
No 3 61 64 95% 
Yes 0 5 5 100% 
Grand total 3 66 69 96% 
 
 
Table 36: Disease Free Period according to Pouch of Douglas Involvement 
Pouch Of Douglas 
Involvement 
Number of 
patients with 
disease free 
period 
< 2 years 
Number of 
patients with 
disease free 
period 
≥ 2 years 
Total number 
of patients 
Probability of 
disease free 
period ≥ 2 
years 
No 8 56 64 88% 
Yes 1 4 5 80% 
Grand Total 9 60 69 87% 
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Table 37: Recurrence rates by Pouch of Douglas Involvement 
Pouch Of Douglas 
Involvement 
Non-Recur Recur Total 
No 54 10 64 
Yes 3 2 5 
Total 57 12 69 
 
Ten out of the 12 patients with recurrence did not have Pouch of Douglas Involvement. 
Pouch of Douglas Involvement however was not statistically significant at the 95% confidence 
level for survival, disease free period or recurrence.  
 
6.7.11. Surgical Margins 
Fifty eight percent had surgical margins that were inadequate at less than or equal to 10mm. 
Forty two percent had adequate surgical margins where tumour was histologically more than 
10mm from the nearest resection margin. 
As shown in previous studies if surgical margins were less than or equal to 10mm probability 
of survival was 93% and probability of being disease free was 78% at 2 years or more which is 
lower compared to that of margins more than 10mm where survival probability was 100% and 
disease-free probability was 100% for the same time period. 
The influence of Surgical Margins on survival period and disease-free period can be seen in the 
tables below. (See Tables 38, 39 and 40) 
 
Table 38: Survival Period according to Surgical Margins 
Surgical Margins Number of 
patients 
surviving 
< 2 years 
Number of 
patients 
surviving 
≥ 2 years 
Total number 
of patients 
Probability of 
survival 
period ≥ 2 
years 
> 10MM 0 29 29 100% 
≤ 10MM 3 37 40 93% 
Grand Total 3 66 69 96% 
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Table 39: Disease Free Period according to Surgical Margins 
Surgical Margins Number of 
patients with 
disease free 
period 
< 2 years 
Number of 
patients with 
disease free 
period 
≥ 2 years 
Total number 
of patients 
Probability of 
disease free 
period ≥ 2 
years 
> 10MM 0 29 29 100% 
≤ 10MM 9 31 40 78% 
Grand Total 9 60 69 87% 
 
Table 40: Recurrence rates by Surgical Margins 
Surgical Margins Non-Recur Recur Total 
> 10MM 27 2 29 
≤ 10MM 30 10 40 
Total 57 12 69 
 
Recurrence rates by Surgical Margins Involvement do not differ significantly at the 95% 
confidence level. However, worth noting was that 10 out of the 12 patients with recurrence had 
surgical margins 10mm. 
 
6.7.12. Post-Operative Cytology 
Average disease-free years (5.35) and average survival years (6.25) were highest for patients’ 
who had post-operative cytology negative for intraepithelial neoplasia and malignancy as 
expected. However, unexpectedly disease-free years and average survival was higher for those 
with HGSIL c.f. those with LGSIL on postoperative cytology. Patients with cytology showing 
radiation reaction postoperatively had the lowest average disease free years (3) and lowest 
average survival years. (See Table 41) 
 
  46  
Table 41: Average Disease Free and Survival Periods by Post-Operative Cytology Results 
Post-operative Cytology Results Average Disease free years Average Survival years 
Negative for Intra-Epithelial Lesion / 
Malignancy 
5.35 6.25 
HGSIL 4.80 5.60 
LGSIL 4.23 4.23 
ASCUS 5.00 5.40 
AGCUS n/a n/a 
Carcinoma-In-Situ n/a n/a 
Radiation Reaction 3.00 3.00 
Other 4.50 4.50 
Not Done 4.09 4.73 
 
6.8. Survival analysis by HIV status 
Quantify survival differences at end of study between HIV positive patients versus HIV negative 
patients. (See Table 42) 
 
Table 42: Comparative rates of mortality by HIV status 
HIV status  Deceased at end 
study 
Still Alive at end of 
study 
Total patients by 
HIV status 
Non-Reactive 5 35 40 
Reactive 4 20 24 
Unknown 1 4 5 
Total number of patients 10 59 69 
    
Mortality rates HIV Non-reactive 12.5%  
  HIV Reactive 16.7%  
  Unknown 20.0%  
 
Survival differences between HIV positive versus HIV negative patients over the full period of 
analysis do not appear to be very different. (See Tables 43 and 44)   
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Table 43: Survival figures 2 years after treatment according to HIV Status 
HIV status Not alive at end 
of 2 years 
Alive at end of 2 
years 
Total 
HIV positive 1 23 24 
HIV negative 2 38 40 
Unknown 0 5 5 
Total 3 66 69 
 
 
Table 44: Survival figures 5 years after treatment according to HIV Status 
HIV status Not alive at end 
of 5 years 
Alive at end of 5 
years 
Total 
HIV positive 3 8 11 
HIV negative 3 23 26 
Unknown 1 4 5 
Total 7 35 42 
 
Fisher Tests performed at the 5% level show that survival differences between HIV positive 
patients versus HIV negative patients are not statistically significant over 2 years or 5 years post 
treatment. 
 
6.9. Recurrence risk of HIV positive patients versus HIV negative patients 
Recurrence risk of HIV positive versus HIV negative patients was also compared as a secondary 
objective. Mortality rates for reactive patients (16.7%) were higher than for non-reactive patients 
(12.5%). (See Table 45) 
 
Table 45: Recurrence rates by HIV Status 
 Number of patients Proportion 
Recurrence rate Non 
Reactive 
Reactive Unknown Non 
Reactive 
Reactive Unknown 
Recurrence 10 1 1 25% 4% 20% 
Non-recurrence 30 23 4 75% 96% 80% 
Total 40 24 5    
Recurrence rate 25% 4%     
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The recurrence rate however was higher in the HIV non-reactive group 25% compared to 4% in 
the HIV reactive group.  Fisher Tests performed at the 95% confidence level show that 
recurrence differences between HIV reactive versus HIV non-reactive patients was statistically 
significant over 2 years post treatment. (See Figure 13) 
 
 
 
 
Disease free years and overall survival distributed by CD4 count bands generally suggests the 
lower the count at diagnosis and management the lower the disease-free period and overall 
survival. (See Figure 14) 
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Number of Recurrences by HIV Status 
Figure 13: Distribution of Recurrences by HIV Status 
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6.10. Surgical and post-surgical complication rate 
Surgical and post-surgical complication rates were also assessed as part of the secondary 
objectives. Intra-operative surgical complication rate was 6% and complications did not include 
any of the common surgical complications that had been identified in previous studies. 
Complications were entered under the group “other” and included unilateral oophorectomy due 
to bleeding in 2 cases and generalized bleeding or difficult haemostasis requiring transfusion due 
to intra-operative anaemia in 2 cases. (See Table 46) 
 
Table 46: Patients by type of Surgical Complication 
Surgical Complications No. Of 
Patients 
 Surgical 
Complication 
Rate 
6% 
Obturator Nerve Resection 0    
Ureteric Resection 0    
Uterine Artery Haemorrhage 0    
Bladder Injury 0    
Other 4    
Nil 65    
Total 69    
 - 
 1.0 
 2.0 
 3.0 
 4.0 
 5.0 
 6.0 
 7.0 
0 to 200 201 to 400 0 to 200 201 to 400 401 to 600 601 to 800 801 to 1000 
Deceased Still Alive 
 
CD4 count 
Average Survival & Disease-Free Periods by CD4 count for HIV Reactive Patients  
(30 June 2015) 
Disease free years 
Overall survival years 
Figure 14: Disease free years and overall survival distributed by CD4 count 
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The immediate post-surgical complication rate was also low at 16%. The most common 
complications were in the category other 4 (6%) and were also complications not identified in 
previous studies – these included: - immediate post-operative anaemia in 1 case requiring 
transfusion, stress incontinence which resolved in 1 case, chylous ascites which resolved in 1 
case and a piece of drain broke off on removal of the drain postoperatively and patient required a 
re-look to remove this piece in 1 case. The next most common complication was wound sepsis 
(4%), followed equally by abdominal hernia (3%) and ileus (3%). (See Figure 15 and Table 47) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Number of patients by type of Immediate Post-Surgical Complication 
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Table 47: Patients split by Immediate Post-Surgical Complications 
Immediate Post-Surgical 
Complications 
No. of patients 
 
Immediate post-
surgical 
complication rate 
16% 
Nil 58    
Other 4    
Wound Sepsis 3    
Abdominal Hernia 2    
Ileus 2    
Haematoma 0    
Uterovaginal Fistula 0    
Pulmonary Embolism 0    
Deep Vein Thrombosis 0    
Lower Limb Oedema 0    
Lymphocyst 0    
Hydro-Ureter 0    
Stress Incontinence 0    
Atonic Bladder 0    
Low Compliance Bladder 0    
Total 69    
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6.11. Post-Surgical Management Complications 
We also assessed the most common complications associated with post-surgical management 
which included either no further management, DXT alone or combined chemotherapy and DXT. 
The patients who did receive post-surgical management complained of one or more 
complications as follows:  46 (67%) had no complications, 12 (17%) had 1 complication, 5 (7%) 
had 2 complications and 6 (9%) had 3 complications. (See Table 48) 
 
Table 48: Post-Surgical Management Complications Rate 
Number of Post-Surgical Management 
Complications 
No. of patients 
0 46 
1 12 
2 5 
3 6 
 69 
Average number of complications per 
patient (overall) 
0.58 
Average number of complications for 
patients who had them 
1.74 
 
 
Thirty-six (52%) of the patients received no further management, 25 (36%) received DXT only 
and 8 (12%) received combined chemotherapy with DXT. The complication rate for combined 
chemotherapy with DXT was highest at 75% compared to DXT alone which was 64%. The 
lowest complication rate was in patients who received no further post-operative management at 
3%. (See Table 49) 
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Table 49: Complication rates by post-surgical management type  
Number of complications per 
patient 
DXT Chemo-
Radiation 
NIL 
0 9 2 35 
1 9 2 1 
2 2 3 0 
3 5 1 0 
Total 25 8 36 
    
Complication rate by Post - 
surgical management type 
64% 75% 3% 
 
The most common complication was diarrhoea / proctitis in 13 patients, skin irritation / rash in 
12, cystitis in 10, nausea and vomiting in 1, hepatotoxicity in 1 and postmenopausal symptoms in 
1. Other complications, not identified for the protocol data collection sheet, were noted in 2 
patients and included a DVT in 1 patient had a mucositis of the introitus. (See Table 50) 
 
Table 50: Number of patients split by Post-Surgical Management Complications 
Post -Surgical Management Complications No. of patients 
affected 
Nil 46 
Proctitis/Diarrhoea 13 
Skin Irritation/Rash 12 
Cystitis/Frequency 10 
Nausea and Vomiting 1 
Hepatotoxicity 1 
Postmenopausal symptoms 1 
Other 2 
Lyphoedema 0 
Alopecia 0 
Mucositis 0 
Electrolyte Disturbances 0 
Anaphylactic Reaction 0 
Fatigue 0 
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Upon review of patient histories it was found that preoperative cytology results were as follows - 
29 (42.03%) were HGSIL, 14 (20.29%) were squamous carcinoma, 5 (7.25%) were HGSIL 
suspicious for invasion. 4 (5.80%) were endocervical adenocarcinoma, 4 (5.8%) were ASCUS, 9 
(13.04%) were negative for intraepithelial lesion/malignancy, 3 (4.35%) did not have 
preoperative cytology and 1 (1.45%) had a LGSIL.  
The postoperative histology results were grouped into squamous carcinoma, adenomatous 
carcinoma and other cell carcinoma. As the total number of patients included in the study is 
relatively small adenosquamous carcinomas were grouped into the adenomatous carcinoma 
group. Squamous cell carcinomas were the majority 54 (78.26%) followed by the Adenomatous 
type cell carcinoma 14 (20.29%) and then other cell carcinomas 1 (1.45%). (See Table 51) 
 
Table 51: Patients by Preoperative Histology Results 
Preoperative Histology Results No. of 
patients 
Squamous Cell Carcinoma 54 
Adenomatous Cell Carcinoma  14 
Other Cell Carcinoma 1 
Total 69 
 
6.12. Surgery analyses 
6.12.1. Surgeries by year by Surgeon 
Over the study period 2002 to 2012 only 3 surgeons performed the operations at Charlotte 
Maxeke Johannesburg Academic Hospital. Two were senior gynaecological oncology 
specialists, surgeons 1 and 2 and one was a sub-speciality fellow training in gynaecological 
oncology, surgeon 3.  
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Over the study period the first surgeon performed 21 operations, the second 27 operations and 
the third 21 operations. The table shows the number of surgeries per surgeon in each year of the 
study. (See Table 52) 
Table 52: Surgeries by year by Surgeon 
Year Surgeon 1 Surgeon 2 Surgeon 3 Total 
2002 3 2 - 5 
2003 - 1 - 1 
2004 1 2 - 3 
2005 - 3 - 3 
2006 2 4 - 6 
2007 1 - - 1 
2008 3 6 - 9 
2009 4 3 - 7 
2010 5 2 - 7 
2011 2 2 2 6 
2012 - 2 19 21 
Grand Total 21 27 21 69 
 
6.12.2. Total Lymph Nodes Removed per Surgery by Surgeon 
The average number of lymph nodes removed by each surgeon per operation was calculated 
and was as follows – surgeon 1 (11.43), surgeon 2 (12.93), surgeon 3 (10.43). (See Table 53) 
Table 53: Total Lymph Nodes Removed per Surgery by Surgeon 
Total Lymph Nodes 
removed per surgery 
Surgeon 1 Surgeon 2 Surgeon 3 
0 to 5 2 6 3 
6 to 10 7 4 8 
11 to 15 8 10 6 
16 to 20 4 4 4 
21 to 25 0 1 0 
26 to 30 0 0 0 
31 to 35 0 1 0 
36 to 40 0 1 0 
Average per 
surgery 
11.43 12.93 10.43 
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6.12.3. Surgical Complications according to Surgeon 
Surgeon 2 had the lowest complication rate at 4%, followed by surgeon 1 with 5%. 
Complications were highest for surgeon 3 at 10%. Average intra-operative complication rate 
was 6%. (See Table 54) 
 
Table 54: Surgical complication rate by Surgeon 
Number of Surgical 
Complications 
Surgeon 1 Surgeon 2 Surgeon 3 Total 
No complications 20 26 19 65 
Complications 1 1 2 4 
     
Surgical 
Complication rate 5% 4% 10% 6% 
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7. DISCUSSION 
The mean age of our study population was 45 years which is slightly lower than that found in a 
large study from Ethiopia where over 1000 women were followed up after surgery and or 
radiotherapy for early stage disease where the mean age was 49 years. 
22 
This may be explained by 
the high incidence of HIV in South Africa where immune compromise causes invasive disease to be 
more aggressive and occur earlier. 
 
According to the South African census of 2011, 48.7% of the population was male and 51.3% was 
female. This almost equal distribution of sex helps us compare the races included in our study. 
Black people are the majority at 79.2 % and this may explain the 68.12% of black patients in our 
study. The census showed that Coloured and White people both formed 8.9% of the total population 
whereas in our study White patients formed 26.09%, and Coloured patients were 2.9% but this may 
be explained by the fact that there are a much higher number of White people living in Gauteng 
province where our hospital is based relative to Coloured people and the opposite is true for the 
Western Province explaining this difference relative to the national race demographic. The census 
showed that 2.5% of the population were Indian, which is close to the 2.9% of Indian patients 
included in our study. 
23
 This indicates that our study was representative of the racial demographic 
in South Africa but that future studies should probably include patients from different hospitals in 
all provinces to improve accuracy of outcomes being assessed.
 
Since the average parity for patients who were alive and dead at the end of the study was 2.86 and 
2.5 respectively and the average gravidity for patients who were alive and dead at the end of the 
study was 3.56 and 2.8 respectively. It would suggest from this study that patients with higher 
numbers of pregnancies and children have a better prognosis if they develop an early stage cervical 
cancer. 
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In 2013 the United Nations Aids Gap Report estimated that 25% of the total 24.7 million HIV 
positive people living in Sub-Saharan Africa were South African. Fifty eight percent of the 24.7 
million were female. 
24
 According to the South African 2011 census there are 26.68 million females 
in the country. 
23
 This implies then that approximately 3.58 million (13.6%) of women in South 
Africa of all age groups are currently HIV positive. In this study 35% of the patients were HIV 
positive – this much higher number relative to the general population may be explained by the fact 
that HIV newly acquired infections are lower in younger populations due to education and 
prevention programs and that most patients in the study and who acquire cervical cancer are of 
middle age. Cervical cancer is also more prevalent in HIV positive patients especially in those with 
low CD4 counts. Our study period was from 2002 to 2012 and anti-retrovirals were only made 
freely available to the population from 2004 and only to patients with CD4 counts below 200. This 
would imply that a large proportion of the HIV positive cohort who had pre-malignant lesions that 
may have regressed on ARV therapy had progressed due to late initiation of therapy. The 
percentage of early stage cervical cancers requiring Wertheim hysterectomies may therefore 
decrease over the next few years with the advent of ARV initiation now occurring at CD4 counts of 
350 and below.  We can assume this since the majority (79%) of HIV positive patients included in 
this study had CD4 counts less than 400. 25% had CD4 counts of 0 to 200 and 54% had CD4 
counts of 201 to 400. Only 8% had CD4 counts of 601 to 1000. 
 
In view of the fact that a Wertheim’s hysterectomy is considered a major surgical procedure and 
that post-surgical recovery an important consideration in overall prognosis. Only patients who are 
relatively healthy and well are selected for the procedure. The majority 83% of patients selected for 
surgery in this study were ECOG performance status 1, i.e. symptomatic but 100% ambulatory. 
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Only 16% were ECOG performance status 0, i.e. asymptomatic. This implies that in this group of 
cervical tumours evaluated as clinically respectable the majority presented with symptomatic 
disease but were otherwise still relatively well.  
 
The study showed that overall survival on 30 June 2015 was 86% which is in keeping with previous 
studies that showed 5 year survival to be between 82 to 90%. 
25 
Overall average disease free period 
was 5 years in our study.  Thirty three percent of the patients were disease free for more than five 
years. 85.51% were disease free for 2 years or more also in keeping with a study that showed 
recurrence free rate at 2 years between 79 to 88%. 
12 
The study results also proved statistically at 
95% confidence that the disease-free interval was highly significant to overall survival both at 2 
years and 5 years postoperatively. We also showed that survival status was higher for patients 
without co-morbidities. A much larger number of patients (21) entered the study in 2012 compared 
to previous years because an oncology fellow joined the group of surgeons that year. It is likely that 
the detection rate of early stage resectable cervical cancer increased for surgical teaching purposes 
in that year. 
 
Adequacy of patient selection for surgery was only 75% and overall 30% of patients were 
incorrectly staged pre-operatively. This led to 25% receiving the incorrect management according 
to our institutions protocols. This suggests that a preoperative MRI scan should be used in addition 
to clinical assessment to correctly identify patients suitable for management by Wertheim’s 
Hysterectomy. A recent prospective study showed MRI scans to be superior to clinical assessment 
with regards to tumour size, internal os and parametrial involvement and that when combined with 
clinical assessment accuracy of correct clinical stage improved significantly. 
26 
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Previous studies have shown that number of positive nodes, tumour cell type, grade, size, depth of 
invasion and lateral spread as well as presence of lymphovascular space, parametrial and Pouch of 
Douglas involvement on histological specimens all impact recurrence risk and rates of patient 
survival and duration of remaining disease free. 
9, 12, 27
   Although similar patterns were observed in 
this study, applying Fisher’s Exact tests for these risk factors did not show statistical significance at 
the 95% confidence level due to the small sample size of this study.
 
Regarding risk factors for recurrence our study showed that an adenomatous subtype was more 
aggressive than a squamous subtype since the overall disease-free period and survival was lower for 
the adenomatous subtype. This is in keeping with other studies which have assessed recurrence risk 
and overall survival relative to tumour histological subtype. 
28, 29
  
Pelvic lymph node metastasis, parametrial invasion and positive surgical margins have been shown 
to be high risk for recurrence as opposed to lymphovascular space invasion, deeper tumour invasion 
and increased tumour size which are relatively considered intermediate risk factors for recurrence. 
9, 
12, 27 
 
In this study tumour size did predict outcome differences. Patients with tumours more than 4cm in 
size had a 75% probability of surviving and a 75% probability of being disease free at 2 or more 
years compared to those who had tumours of 4cm and less in size who had a 97% probability of 
survival and an 88% probability of being disease free at 2 years or more.  
This was also the case with depth of invasion where both the 2 year or more probability of survival 
and being disease free was 100% for tumours less than or equal to 3mm and for tumours with depth 
3mm and more but less than 5mm - this decreased to 93% and 80% for tumours more than 5mm in 
depth.  
Patients with tumours that had spread laterally less than or equal to 7mm had 100% probability of 
survival and 95% probability of being disease free at 2 years or more compared to those with 
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tumours more than 7mm where survival probability decreased to 94% and disease-free probability 
decreased to 83%.  
Patients with lymphovascular space invasion had lower probabilities of survival and being disease 
free 2 years postoperatively relative to those without lymphovascular space invasion 96% and 92% 
as opposed to 95% and 74%. These differences were not very high showing then that indeed 
lymphovascular space involvement is more of an intermediate risk factor for recurrence.  
With regards to pelvic lymph node involvement patients’ probability of surviving 2 or more years 
postoperatively irrespective of the number of positive lymph nodes was high. However, generally 
the  probability rate of being disease free 2 or more years postoperatively decreased exponentially 
with increasing number of positive nodes harvested at surgery. One patient with 6 positive nodes 
was disease free at 2 or more years postoperatively indicating that a good 2 year outcome may still 
be achieved if bimodal adjuvant therapy is used to decrease recurrence and that it definitely 
increases patient survival in the 2 or more years postoperative time period. 
Interestingly, patients with parametrial and or pouch of Douglas involvement had a reduced 2 year 
probability of being disease free but their survival probability was marginally higher compared to 
those patients who had no involvement.  These differences may be attributed to the smaller sample 
size of patients who did have involvement of either the parametria or pouch of Douglas or it may 
indicate that these risk factors are less predictive of short term survival compared to other risk 
factors assessed by the study. 
Positive margins are considered margins where tumour was found less than 10mm from the 
resection borders histologically. Our study showed an 7% decrease in the 2 year probability of 
survival and a 22% decrease in the 2 year probability of being disease free if tumour was not more 
than or equal to 10mm from the resection borders. Eighty three percent of patients with positive 
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margins in this study had recurrence which is therefore in keeping with what other studies have 
shown that positive margins are a high risk factor for recurrence. 
Survival and disease free intervals were highest for patients with post-operative cytology showing 
negative for intra-epithelial lesion or malignancy and lowest for patients with cytology showing 
radiation reaction. This is likely due to the latter patients having had more risk factors for 
recurrence which necessitated the use of adjuvant radiotherapy compared to the others who had 
complete resection and no risk factors for recurrence.   
 
In general the results showed that HIV non reactive patients had longer survival and disease free 
periods than those who were HIV reactive. Reactive patients tended to have a similar number of 
disease free years to overall survival – implying that patients demised soon after recurrence. Non 
reactive patients lived with recurrence for longer. Although the statistics for patients with unknown 
HIV status appear higher than those with known HIV status – there were only 5 patients in the 
unknown category and hence the results were not statistically significant.  
The study also showed that for HIV reactive patients the lower the CD4 count at diagnosis and 
management, the lower the disease-free period and overall survival. This suggests that all HIV 
positive women with confirmed malignancies should be on antiretroviral therapy or initiated 
immediately if already not on treatment. Furthermore, patients should be counselled on increased 
risk of cervical cancer recurrence if they default treatment at a later stage if tumour is successfully 
excised with no risk factors requiring adjuvant therapy. 
 
Both the intra-operative surgical complication rate (6%) and the immediate post-surgical 
complication rate (16%) was low this may be due to the fact that only 3 senior surgeons performed 
all the surgeries – 2 of which were experienced gynaecological oncology surgeons and 1 a 
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gynaecological oncology fellow. The numbers of lymph nodes harvested by all 3 surgeons was 
similar and the complication rate for the 2 more experienced surgeons was similar 5% and 4% and 
lower compared for that of the fellow which was 10%. The cumulative complication rate for our 
institution was therefore 22% with no mortalities but is slightly higher than the 16, 5% found in a 
very similar study done over 5 years that followed up 115 patients.
 30
  
 
A high percentage of patients 47.83% required adjuvant therapy either radiation only or chemo-
radiation. The most common early complications of the adjuvant therapy were proctitis or 
diarrhoea, then skin irritation and rashes followed by cystitis and frequency.  
 
8. LIMITATIONS 
Due to the small sample size, some results need to be interpreted with care especially where a 
category was represented by a small number of patients. A larger sample size would be preferable 
to draw conclusions with statistical significance.  
Another limitation of the study was that 10 patients could not be reached telephonically or at their 
home addresses at the cut-off date for data collection. Their survival status was confirmed by the 
Department of Home Affairs but their disease-free interval was assumed to be at their last follow up 
date at our hospital. If these patients relocated and continued follow up at different hospitals the 
assumed disease-free interval and survival without recurrence for these 10 patients would be 
incorrect. 
Patients included in the study were representative of the racial group demographic in the country 
except for white and coloured patients. White patients had a higher representation and Coloured 
patients a lower presentation as compared to that in the country but were correctly represented for 
the province of Gauteng. Future similar studies need to be done in hospitals in more than one 
province to better represent the racial demographic of the country. 
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The patients in our study also only represent those of middle and low socio-economic groups since 
most South Africans who are affluent have self-funded medical aids and are not treated at 
government institutions but at private hospitals. We can thus not comment on what differences 
socio-economic status might have on survival and disease-free periods with this disease. 
 
This study relied on retrospective data and missing data was anticipated. Where information was 
missing patients were asked when contacted telephonically regarding their follow up and well-
being.  
Patients with complications may not have necessarily returned to CMJAH – these unknown losses 
to follow-up may have given biased complication rates.  
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ABBREVIATIONS 
CMJAH Charlotte Maxeke Johannesburg Academic Hospital 
CRT Chemo-radiotherapy 
DXT Deep X Ray Therapy (adjuvant radiotherapy) 
ECOG European Cooperative Oncology Group 
FIGO Fédération Internationale de Gynécologie et d'Obstétrique (International Federation 
of Gynaecology and Obstetrics) 
HIV Human Immunodeficiency Virus 
LVSI Lympho-Vascular Space Invasion  
NHLS National Health Laboratory Services 
POD Pouch of Douglas 
RT Radiotherapy  
WHO World Health Organisation 
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APPENDICES 
APPENDIX 1:  DATA COLLECTION SHEET 
1. NAME OF SURGEON 
 
2. PATIENT ID 
 
3. AGE 
 
4. RACE 
 
5. PARITY 
 
6. CO-MORBIDITIES 
  DIABETES MELLITUS 
  EPILEPSY 
  ASTHMA 
  COPD 
  HEART DISEASE 
  HYPERTENSION 
  OTHER 
 
7. HIV STATUS 
  REACTIVE   CD4 COUNT ………  
  NON-REACTIVE 
  UNKNOWN 
 
8. ECOG PERFORMANCE STATUS 
  0 ASYMPTOMATIC 
  1 SYMPTOMATIC 100% AMBULATORY 
  2 SYMPTOMATIC > 50% AMBULATORY 
  3 SYMPTOMATIC < 50% AMBULATORY 
  4 BED-BOUND 
  5 DEATH 
 
  
  72  
9. PREOPERATIVE CYTOLOGY RESULTS 
  HGSIL 
  LGSIL 
  ASCUS 
  AGCUS 
  HGSIL SUSPICIOUS FOR INVASION 
  SQUAMOUS CARCINOMA 
  ENDOCERVICAL ADENOCARCINOMA 
  NIL 
 
10. PREOPERATIVE HISTOLOGY RESULTS 
  SQUAMOUS CELL CARCINOMA 
  ADENOMATOUS CELL CARCINOMA  
  OTHER CELL CARCINOMA 
 
11.  PREOPERATIVE CLINICAL STAGING 
  STAGE IB1 
  STAGE IB2 
 
12. DATE OF SURGERY 
  
13. POST-OPERATIVE  HISTOLOGY CELL TYPE 
  SQUAMOUS CELL CARCINOMA 
  ADENOMATOUS CELL CARCINOMA 
  OTHER CELL CARCINOMA 
 
14.  POSTOPERATIVE HISTOLOGY STAGE 
  STAGE IA1 
  STAGE IA2 
  STAGE IB1 
  STAGE IB2  
  STAGE IIA 
  STAGE II B 
  STAGE IIIA 
  STAGE IIIB 
  STAGE IVA 
  STAGE IVB 
 
15.  TUMOUR GRADE 
  POORLY DIFFERENTIATED 
  MODERATELY DIFFERENTIATED 
  WELL DIFFERENTIATED 
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16.  TUMOUR SIZE 
    4CM 
  > 4CM 
 
17.  TUMOUR DEPTH OF INVASION 
  < 3MM 
  > 3MM 
  < 5MM 
  > 5MM 
 
18.  TUMOUR LATERAL SPREAD 
  < 7MM 
  > 7MM 
 
19.  LYMPHOVASCULAR SPACE INVOLVEMENT 
  YES 
  NO 
 
20.  NUMBER OF POSITIVE LYMPH NODES 
 
21. TOTAL LYMPH NODES REMOVED 
 
22.  PARAMETRIAL INVOLVEMENT 
  YES 
  NO 
 
23.  POUCH OF DOUGLAS INVOLVEMENT 
  YES 
  NO 
 
24. SURGICAL MARGINS 
  ≥ 10MM 
  < 10MM 
 
25. SURGICAL COMPLICATIONS 
  OBTURATOR NERVE RESECTION 
  URETERIC RESECTION 
  UTERINE ARTERY HAEMORRHAGE 
  BLADDER INJURY 
  OTHER 
  NIL 
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26. IMMEDIATE POST SURGICAL COMPLICATIONS 
  HAEMATOMA 
  UTEROVAGINAL FISTULA 
  PULMONARY EMBOLISM 
  DEEP VEIN THROMBOSIS 
  WOUND SEPSIS 
  ABDOMINAL HERNIA 
  ILEUS 
  LOWER LIMB OEDEMA 
  LYMPHOCYST 
  HYDRO-URETER 
  STRESS INCONTINENCE 
  ATONIC BLADDER 
  LOW COMPLIANCE BLADDER 
  OTHER 
  NIL 
 
27. POST SURGICAL MANAGEMENT 
  DXT 
  CHEMOTHERAPY 
  CHEMO-RADIATION 
 
28. POST SURGICAL MANAGEMENT COMPLICATIONS 
  PROCTITIS/DIARRHOEA 
  CYSTITIS/FREQUENCY 
  NAUSEA AND VOMITING 
  SKIN IRRITATION/RASH 
  LYPHOEDEMA 
  ALOPECIA 
  OTOTOXICITY 
  OCULAR TOXICITY 
  HEPATOTOXICITY 
  NEUROTOXICITY 
  NEPHROTOXICITY 
  MYELOSUPRESSION 
  ELECTROLYTE DISTURBANCES 
  ANAPHYLACTIC REACTION 
  FATIGUE 
  OTHER 
  NIL 
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29. POST-OPERATIVE CYTOLOGY RESULTS 
  NEGATIVE FOR INTRA-EPITHELIAL LESION / MALIGNANCY 
  HGSIL 
  LGSIL 
  ASCUS 
  AGCUS 
  CARCINOMA-IN-SITU 
  NOT DONE 
 
30. NUMBER OF YEARS FOLLOWED UP POST-OPERATIVELY 
 
31. NUMBER OF YEARS DISEASE FREE POST-OPERATIVELY 
 
32. NUMBER OF YEARS OVERALL SURVIVAL 
 
33. SURVIVAL STATUS AT 30/06/2015 
 
34. DATE OF DEATH 
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APPENDIX 2:  PERMISSION LETTERS 
 
Figure 16: Permission from CMJAH CEO 
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Figure 17: Permission from Head of Anatomical Pathology 
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Figure 18: Permission from Head of Obstetrics and Gynaecology 
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Figure 19: Permission from Senior Specialist of Radiation Oncology 
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Figure 20: Confirmation of Study Approval from Human Research Ethics Committee 
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Figure 21: Clearance Certificate from Human Research Ethics Committee 
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APPENDIX 3: TURNITIN REPORT 
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